A Phase I / II Clinical Study Of Enadenotucirev Administered Intraperitoneally: Dose Finding and Proof of Concept in Platinum-Resistant Epithelial Ovarian Cancer.
Phase of Trial: Phase I/II
Latest Information Update: 22 Mar 2018
At a glance
- Drugs Enadenotucirev (Primary) ; Paclitaxel
- Indications Ovarian cancer
- Focus Adverse reactions; Proof of concept
- Acronyms OCTAVE
- Sponsors PsiOxus Therapeutics
- 20 Mar 2018 Planned End Date changed from 1 Jan 2018 to 1 Dec 2018.
- 20 Mar 2018 Planned primary completion date changed from 1 Nov 2017 to 1 Jul 2018.
- 08 Sep 2016 Planned End Date changed from 1 Mar 2017 to 1 Jan 2018.